AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2741619 — intervention group
Group type: COMPARATOR
Intervention: Standardized intravenous fluids
Number of subjects: 2
Study 4595181 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam (Valium)
Number of subjects: 12
Study 4595181 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol (Inderal)
Number of subjects: 12
Study 4595181 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 29908804 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic milking system (AMS)
Number of subjects: 90
Study 29908804 — intervention group
Group type: COMPARATOR
Intervention: Tandem milking (Control)
Number of subjects: 90
Study 26799528 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-level implants with mucosal thickness ≤2 mm (Group A, MC)
Number of subjects: 33
Study 26799528 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-level implants with mucosal thickness >2 mm (Group B, MC)
Number of subjects: 33
Study 26799528 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-level implants with mucosal thickness ≤2 mm (Group A, LC)
Number of subjects: 33
Study 26799528 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-level implants with mucosal thickness >2 mm (Group B, LC)
Number of subjects: 33
Study 25727892 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalosis (ALK; 0.3 g (kg body weight)(-1) sodium bicarbonate)
Number of subjects: 11
Study 25727892 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA; 0.3 g (kg body weight)(-1) calcium carbonate)
Number of subjects: 11
Study 23531267 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative peer influence (unsafe decisions)
Number of subjects: 80
Study 23531267 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive peer influence (cautious decisions)
Number of subjects: 80
Study 23531267 — intervention group
Group type: COMPARATOR
Intervention: Silent peer (no influence)
Number of subjects: 80
Study 23531267 — intervention group
Group type: COMPARATOR
Intervention: No peer (completed task alone)
Number of subjects: 80
Study 21998287 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for early syphilis
Number of subjects: 465
Study 18293426 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 553
Study 18293426 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) as part of local treatment
Number of subjects: 553
Study 16595098 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief counselling plus nursing follow-up
Number of subjects: 125
Study 16595098 — intervention group
Group type: COMPARATOR
Intervention: Brief counselling from the doctor (control group)
Number of subjects: 125
Study 12533330 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg glatiramer acetate (GA)
Number of subjects: 239
Study 12533330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 10894863 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide, leucovorin, and bolus fluorouracil (ELF)
Number of subjects: 399
Study 10894863 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusional fluorouracil plus cisplatin (FUP)
Number of subjects: 399
Study 10894863 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil, doxorubicin, and methotrexate (FAMTX)
Number of subjects: 399
Study 10894863 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 399
Study 10894863 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicity
Number of subjects: 399
Study 10894863 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related deaths
Number of subjects: 399
Study 9184261 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium salts (specific types not detailed)
Number of subjects: 0
Study 9184261 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Number of subjects: 0
Study 9184261 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium citrate
Number of subjects: 0
Study 9184261 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium gluconolactate
Number of subjects: 0
Study 9184261 — intervention group
Group type: EXPERIMENTAL
Intervention: Ossein-hydroxyapatite complex
Number of subjects: 0
Study 9184261 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 8300824 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione therapy (600 mg i.m. injection every other day for 2 months)
Number of subjects: 20
Study 8300824 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equal volume of a placebo preparation for 2 months)
Number of subjects: 20
Study 3814032 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (4 mg X 70 kg‐1 body weight)
Number of subjects: 0
Study 3814032 — intervention group
Group type: COMPARATOR
Intervention: 2-PAM chloride (up to 1200 mg X 70 kg‐1 body weight)
Number of subjects: 0
Study 28803744 — intervention group
Group type: EXPERIMENTAL
Intervention: NER1006
Number of subjects: 621
Study 28803744 — intervention group
Group type: COMPARATOR
Intervention: trisulfate
Number of subjects: 621
Study 27938540 — intervention group
Group type: EXPERIMENTAL
Intervention: H2∶O2 mixture (66.67%∶33.33%) inhalation for 1 hour per day for 30 days
Number of subjects: 96
Study 27938540 — intervention group
Group type: COMPARATOR
Intervention: N2∶O2 mixture (66.67%∶33.33%) inhalation for 1 hour per day for 30 days
Number of subjects: 96
Study 24955451 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-L polyethylene glycol + ascorbic acid (PEG + Asc)
Number of subjects: 327
Study 24955451 — intervention group
Group type: COMPARATOR
Intervention: 4-L polyethylene glycol (4-L PEG)
Number of subjects: 327
Study 24343290 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 17
Study 24343290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 21506146 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Hz STN DBS
Number of subjects: 11
Study 21506146 — intervention group
Group type: COMPARATOR
Intervention: 130 Hz STN DBS
Number of subjects: 11
Study 21506146 — intervention group
Group type: COMPARATOR
Intervention: defined Off
Number of subjects: 11
Study 18436114 — intervention group
Group type: EXPERIMENTAL
Intervention: Darapladib 40 mg
Number of subjects: 959
Study 18436114 — intervention group
Group type: EXPERIMENTAL
Intervention: Darapladib 80 mg
Number of subjects: 959
Study 18436114 — intervention group
Group type: EXPERIMENTAL
Intervention: Darapladib 160 mg
Number of subjects: 959
Study 18436114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 959
Study 16573804 — intervention group
Group type: EXPERIMENTAL
Intervention: Eudragit-L-coated mesalazine tablets
Number of subjects: 215
Study 16573804 — intervention group
Group type: COMPARATOR
Intervention: Ethylcellulose-coated mesalazine tablets
Number of subjects: 215
Study 12679312 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 60 mg BID
Number of subjects: 10
Study 12679312 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 90 mg BID
Number of subjects: 10
Study 12679312 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 60 mg thrice daily
Number of subjects: 10
Study 12679312 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 90 mg thrice daily
Number of subjects: 10
Study 12679312 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 120 to 270 mg/day
Number of subjects: 10
Study 12679312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10743870 — intervention group
Group type: EXPERIMENTAL
Intervention: Sadness
Number of subjects: 0
Study 10743870 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger
Number of subjects: 0
Study 10743870 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-specific bias
Number of subjects: 0
Study 10743870 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive effort
Number of subjects: 0
Study 9013088 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/NETA (continuous oral 17 beta‐oestradiol 2 mg day‐1 and norethisterone acetate 1 mg day‐1)
Number of subjects: 75
Study 9013088 — intervention group
Group type: COMPARATOR
Intervention: E2/MPA (transdermal 17 beta‐oestradiol 50 micrograms day‐1 with oral cyclic medroxyprogesterone acetate 10 mg day‐1 on days 17-28)
Number of subjects: 75
Study 1524955 — intervention group
Group type: EXPERIMENTAL
Intervention: Bestatin (30 mg orally daily for three months after molar deliveries)
Number of subjects: 49
Study 1524955 — intervention group
Group type: COMPARATOR
Intervention: Bestatin non-administered group
Number of subjects: 49
Study 1524955 — intervention group
Group type: EXPERIMENTAL
Intervention: Bestatin
Number of subjects: 49
Study 3883421 — intervention group
Group type: EXPERIMENTAL
Intervention: Meglumine/sodium diatrizoate (60%)
Number of subjects: 31
Study 3883421 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix (new monoacidic dimer)
Number of subjects: 31
Study 31471444 — intervention group
Group type: EXPERIMENTAL
Intervention: Taiji exercise for 10 weeks
Number of subjects: 80
Study 31471444 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise for 10 weeks
Number of subjects: 80
Study 31471444 — intervention group
Group type: EXPERIMENTAL
Intervention: Taiji exercise and Aerobic exercise
Number of subjects: 80
Study 29227294 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (EXE: arm crank ergometer, 30 min)
Number of subjects: 9
Study 29227294 — intervention group
Group type: COMPARATOR
Intervention: Control session (CON: participants remained seated on the cycle ergometer, 30 min)
Number of subjects: 9
Study 26764063 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) with a self-expanding prosthesis
Number of subjects: 0
Study 26764063 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 0
Study 24751369 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sense-of-control
Number of subjects: 106
Study 24751369 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sense-of-control
Number of subjects: 106
Study 24751369 — intervention group
Group type: COMPARATOR
Intervention: No-intervention
Number of subjects: 106
Study 23689969 — intervention group
Group type: EXPERIMENTAL
Intervention: Neydharting mud-pack therapy
Number of subjects: 53
Study 23689969 — intervention group
Group type: COMPARATOR
Intervention: Control group (hot packs)
Number of subjects: 53
Study 20219528 — intervention group
Group type: EXPERIMENTAL
Intervention: Active commuting (defined as engaging in physical activity during commuting)
Number of subjects: 7280
Study 20219528 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent on walking or cycling during commuting
Number of subjects: 7280
Study 20219528 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-demographic factors (residency, education, income, occupational PA)
Number of subjects: 7280
Study 20219528 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking and leisure-time physical activity
Number of subjects: 7280
Study 18201563 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg pravastatin/day
Number of subjects: 40
Study 18201563 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg pravastatin/day
Number of subjects: 40
Study 15844022 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasobiliary drain (NBD)
Number of subjects: 150
Study 15844022 — intervention group
Group type: COMPARATOR
Intervention: Stent placement
Number of subjects: 150
Study 12757964 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg/day)
Number of subjects: 30
Study 12757964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10484842 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (accelerated radiotherapy, 20 Gy in 5 fractions)
Number of subjects: 123
Study 10484842 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 123
Study 8554936 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-flurbiprofen (50 mg)
Number of subjects: 16
Study 8554936 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-flurbiprofen (50 mg)
Number of subjects: 16
Study 8554936 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-flurbiprofen (100 mg)
Number of subjects: 16
Study 8554936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2111665 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisoylated plasminogen streptokinase activator complex (APSAC): 30 IU in 5 minutes
Number of subjects: 231
Study 2111665 — intervention group
Group type: COMPARATOR
Intervention: Heparin therapy (5,000 IU)
Number of subjects: 231
Study 646300 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 76
Study 646300 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 76
Study 31092252 — intervention group
Group type: EXPERIMENTAL
Intervention: Elements virtual rehabilitation (three weekly 30-40 min sessions for four weeks) combined with treatment as usual
Number of subjects: 21
Study 31092252 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual alone
Number of subjects: 21
Study 28049742 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-frequency ventilation (up to 150 breaths/min)
Number of subjects: 12
Study 28049742 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (≤60 breaths/min)
Number of subjects: 12
Study 24786228 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure (HBP) measurements
Number of subjects: 400
Study 24786228 — intervention group
Group type: COMPARATOR
Intervention: Clinic Blood Pressure (CBP) measurements
Number of subjects: 400
Study 23392747 — intervention group
Group type: EXPERIMENTAL
Intervention: HCl (0.1 N) infusion
Number of subjects: 16
Study 23392747 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 16
Study 20385397 — intervention group
Group type: EXPERIMENTAL
Intervention: TachoSil
Number of subjects: 119
Study 20385397 — intervention group
Group type: COMPARATOR
Intervention: ABC
Number of subjects: 119
Study 18804988 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation for 12 weeks
Number of subjects: 0
Study 18804988 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 0
Study 16686762 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Number of subjects: 314
Study 16686762 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CyA)
Number of subjects: 314
Study 14747672 — intervention group
Group type: EXPERIMENTAL
Intervention: IMCI-derived nutrition counseling protocol training for physicians
Number of subjects: 0
Study 14747672 — intervention group
Group type: COMPARATOR
Intervention: Control group without continuing education in nutrition
Number of subjects: 0
Study 11098966 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition enriched with arginine and glutamate (GlnP+ group)
Number of subjects: 15
Study 11098966 — intervention group
Group type: COMPARATOR
Intervention: Conventional total parenteral nutrition (control group)
Number of subjects: 15
Study 9203170 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline 1000 mg/day
Number of subjects: 24
Study 9203170 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline 500 mg/day
Number of subjects: 24
Study 9203170 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline 300 mg/day + Nimodipine 90 mg/day
Number of subjects: 24
Study 8315428 — intervention group
Group type: EXPERIMENTAL
Intervention: PCNU 100 mg/m2 every 7 weeks for 1 year and every 10 weeks for the second year
Number of subjects: 346
Study 8315428 — intervention group
Group type: COMPARATOR
Intervention: BCNU 200 mg/m2 every 7 weeks for 1 year and every 10 weeks for the second year
Number of subjects: 346
Study 2426118 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (SP) 65 micrograms
Number of subjects: 13
Study 2426118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 29361312 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous interpectoral block (CIPB) with 30mL of 0.5% ropivacaine and postoperative perfusion of ropivacaine 0.2% 5mL·h‐1; PCA bolus 5mL/30minutes for 24 hours
Number of subjects: 137
Study 29361312 — intervention group
Group type: COMPARATOR
Intervention: Intravenous analgesia (IV) with fentanyl, metamizole, dexketoprofen, ondansetron, and postoperative perfusion of metamizole 4%, tramadol 0.2%, ondansetron 0.08% 2ml·h‐1; PCA bolus 2mL/20min for 24 hours
Number of subjects: 137
Study 27219522 — intervention group
Group type: EXPERIMENTAL
Intervention: DE‐EBRT with bicalutamide 150 mg once daily for 5 months
Number of subjects: 252
Study 27219522 — intervention group
Group type: COMPARATOR
Intervention: DE‐EBRT without hormone therapy
Number of subjects: 252
Study 27219522 — intervention group
Group type: EXPERIMENTAL
Intervention: DE‐EBRT with bicalutamide
Number of subjects: 252
Study 27219522 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose escalation to >75.6 Gy
Number of subjects: 252
Study 25044219 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral 600 mg dose of linezolid (LZD)
Number of subjects: 18
Study 25044219 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (LZD) administration timing
Number of subjects: 18
Study 22950484 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 1 μg.kg(‐1) (Group 1)
Number of subjects: 116
Study 22950484 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 2 μg.kg(‐1) (Group 2)
Number of subjects: 116
Study 20819564 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcon-60s (3 cycles of 60-second balloon deflation and inflation)
Number of subjects: 75
Study 20819564 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcon-30s (3 cycles of 30-second balloon deflation and inflation)
Number of subjects: 75
Study 20819564 — intervention group
Group type: COMPARATOR
Intervention: Routine group (no intervention)
Number of subjects: 75
Study 20819564 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcon-60s
Number of subjects: 75
Study 20819564 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcon-30s
Number of subjects: 75
Study 20819564 — intervention group
Group type: COMPARATOR
Intervention: Routine group
Number of subjects: 75
Study 18460987 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (measured using an accelerometer over 6 days)
Number of subjects: 1440
Study 18460987 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat and fat-free mass along with racial group
Number of subjects: 1440
Study 18460987 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity added to the regression model
Number of subjects: 1440
Study 18460987 — intervention group
Group type: EXPERIMENTAL
Intervention: Racial group (Black girls)
Number of subjects: 1440
Study 15971198 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (CBI), 10-contact, 20-week duration
Number of subjects: 0
Study 15971198 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 12052364 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanoemission chaos estimation in blood of gastric cancer patients
Number of subjects: 0
Study 12052364 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 0
Study 12052364 — intervention group
Group type: COMPARATOR
Intervention: Patients with inflammation of gastric mucosa
Number of subjects: 0
Study 10474783 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet (25% fat)
Number of subjects: 25
Study 10474783 — intervention group
Group type: COMPARATOR
Intervention: High fat diet (40% fat)
Number of subjects: 25
Study 8981710 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with TPA
Number of subjects: 96
Study 1985608 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg once daily
Number of subjects: 8245
Study 1985608 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg once daily
Number of subjects: 8245
Study 1985608 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg twice daily
Number of subjects: 8245
Study 1985608 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg twice daily
Number of subjects: 8245
Study 1985608 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 80 mg daily
Number of subjects: 8245
Study 1985608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8245
Study 1985608 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg daily
Number of subjects: 8245
Study 1985608 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg daily
Number of subjects: 8245
Study 6878616 — intervention group
Group type: EXPERIMENTAL
Intervention: Health surveillance and health education (Experiment 2)
Number of subjects: 0
Study 6878616 — intervention group
Group type: EXPERIMENTAL
Intervention: Health surveillance (Experiment 1)
Number of subjects: 0
Study 6878616 — intervention group
Group type: COMPARATOR
Intervention: Control school
Number of subjects: 0
Study 30773934 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone implant (Ozurdex®)
Number of subjects: 28
Study 28903954 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein protein
Number of subjects: 38
Study 28903954 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein
Number of subjects: 38
Study 28903954 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (Control)
Number of subjects: 38
Study 26524815 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical nutrition guidance (EG, n = 124)
Number of subjects: 261
Study 23375114 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery Line plus Treatment-as-Usual (TAU)
Number of subjects: 36
Study 23375114 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 36
Study 21107305 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g mycophenolate mofetil (group A, n=75)
Number of subjects: 150
Study 21107305 — intervention group
Group type: COMPARATOR
Intervention: 1.440 g enteric-coated mycophenolate sodium (group B, n=75)
Number of subjects: 150
Study 19008470 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid treatment for 6 weeks
Number of subjects: 0
Study 19008470 — intervention group
Group type: COMPARATOR
Intervention: Folic acid, vitamin B(12), and vitamin B(6) treatment for 3 months
Number of subjects: 0